Cancer Vaccines: Moving toward Prevention?

After several decades of research, recent successful phase III controlled clinical trials have renewed enthusiasm for vaccine treatment of cancer. This perspective on the report by Berta and colleagues in this issue of the journal (beginning on page 994) discusses the potential prevention of oral cancer through vaccine strategies and, in the broader context, ideal characteristics of tumor antigens as candidates for vaccines for both treating and preventing cancer, potential primary and secondary prevention settings for vaccines, desirable types of immune effectors induced by vaccines, and safety. Cancer Prev Res; 4(7); 954–6. ©2011 AACR.

[1]  J. Gariépy,et al.  Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon Cancer , 2010, Cancer Prevention Research.

[2]  M. Disis.  The Ultimate in Cancer Chemoprevention: Cancer Vaccines , 2010, Cancer Prevention Research.

[3]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[4]  L. Kwak,et al.  Therapeutic lymphoma vaccines: importance of T-cell immunity , 2006, Expert review of vaccines.

[5]  N. Kemeny,et al.  Colorectal hepatic metastases: adjuvant chemotherapy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Shravan Madireddi,et al.  Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. , 2007, Current opinion in investigational drugs.

[7]  P. Musiani,et al.  A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters , 2011, Cancer Prevention Research.

[8]  P. Hwu,et al.  A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Berry,et al.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Arteaga.  Inhibiting Tyrosine Kinases: Successes and Limitations , 2003, Cancer biology & therapy.

[11]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[12]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  An autoimmune-mediated strategy for prophylactic breast cancer vaccination. , 2010, Women's health.

[14]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.